Skip to content

Author

Hamed Mohammadi

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Economic evaluation of tirzepatide, semaglutide, and liraglutide in the treatment of obese and overweight patients without diabetes: a short-term cost-effectiveness analysis in Iran

Although tirzepatide provided greater health benefits, its higher cost limited its cost-effectiveness at current prices, and semaglutide was the cost-effective injectable GLP-1-1-based therapy in Iran.

Negin Reiszadeh, R. Radmanesh, R. Heshmat et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.